Insulet Corporation (PODD) is well-poised to gain in the coming quarters, backed by the strength of its revolutionary Omnipod 5 Automated Insulin Delivery (“AID”) system. The continued market expansion of Omnipod DASH is also highly encouraging.  Strong solvency is an added upside.  Meanwhile, the company’s sole dependency on the Omnipod system and intense competitive pressure remain concerns for its operations.  In the past year, this Zacks Rank #2 (Buy) stock has decreased 47.9% against the 6.6% rise of t ...